4D-150 in Patients With Diabetic Macular Edema
← catalyst calendarNCT05930561 · readout in 924 d
Sponsored by 4D Molecular Therapeutics (industry) · FDMT — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · Double · Treatment
Enrollment
72estimated
Sites
6
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-09 | actual | When the study began enrolling |
| Primary completion | 2029-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetic Macular Edema
- Diabetic Retinopathy
Interventions
- Biological: 4D-150 IVT
- Biological: Aflibercept IVT — also filed as Eylea
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of TEAEs and SAEs, including clinically significant changes in safety parameters (Part 1)
measured 60 months
Annualized number of aflibercept injections in the study eye (Part 2)
measured 52 weeks
Publications
- PMID 39620832 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · FDMT's whole pipeline · Catalyst calendar · Every registered study · What changed